By Fineline Cube 
China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), based in China, announced that its independently developed heart valve balloon dilatation catheter, Alwide Plus, has received CE Mark approval in the European Union. This approval underscores the product’s compliance with EU safety and performance standards.
Product Profile
Alwide Plus is designed to dilate calcified aortic valves prior to transcatheter aortic valve implantation (TAVI), streamlining the valvuloplasty procedure. Since receiving approval from China’s National Medical Products Administration in August 2021, Alwide Plus has secured registration in over a dozen overseas markets.
Global Recognition
The CE Mark approval marks a significant milestone for MicroPort CardioFlow, facilitating market expansion and reinforcing the company’s commitment to advancing cardiovascular treatments globally.-Fineline Info & Tech